Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Castle Biosciences (CSTL)
NASDAQ:CSTL
Holding CSTL?
Track your performance easily
CSTL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$16.97 - $35.84
Previous Close$26.52
Volume355.68K
Average Volume (3M)386.16K
Market Cap
$742.75M
Enterprise Value$489.69M
Total Cash (Recent Filing)$279.80M
Total Debt (Recent Filing)$26.74M
Price to Earnings (P/E)132.7
Beta1.09
Next Earnings
Mar 04, 2025EPS Estimate
<$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.20
Shares Outstanding28,007,301
10 Day Avg. Volume337,306
30 Day Avg. Volume386,158
Standard Deviation0.17
R-Squared0.08
Alpha0.00571
Financial Highlights & Ratios
Price to Book (P/B)1.68
Price to Sales (P/S)2.53
Price to Cash Flow (P/CF)8.40
P/FCF Ratio11.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.57
Enterprise Value/Gross Profit2.80
Enterprise Value/Ebitda19.54
Forecast
1Y Price Target
$42.29Price Target Upside56.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Castle Biosciences News
PremiumCompany Announcements
Castle Biosciences Reports Strong Q3 2024 Growth
PremiumCompany Announcements
Castle Biosciences Reports Strong Q3 2024 PerformanceBulls Say, Bears Say
Bulls Say
Financial PerformanceCastle Biosciences reported strong revenue of $86.3M in the third quarter, significantly beating estimates.
Growth PotentialThe TissueCypher test is highlighted in practice guidelines and has a large market opportunity with only 5.5% penetration, indicating significant growth potential.
Market PositionCastle Biosciences is seen as a leading skin cancer diagnostics company rooted in genomics with a large total addressable market of $8B.
Bears Say
Regulatory ChallengesMolDx finalized and maintained a non-coverage decision for CSTL's DecisionDx-Squamous Cell Carcinoma test, leaving Novitas' Oncology LCD finalization as a potential next step in the resolution of coverage questions.
Revenue ImpactPotential near term loss of a growth driver in DDx-SCC, which was about 20% of CSTL's 1Q24 revenue.
Uncertainty In ReimbursementFuture coverage for DDx-SCC remains uncertain as Palmetto continues to noncover the test, and Novitas' decision on oncology LCD is pending.
---
Ownership Overview
2.93% Insiders
26.47% Mutual Funds
35.96% Other Institutional Investors
20.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CSTL FAQ
What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $16.96 and its highest was $35.84 in the past 12 months.
What is Castle Biosciences’s market cap?
Currently, no data Available
When is Castle Biosciences’s upcoming earnings report date?
Castle Biosciences’s upcoming earnings report date is Mar 04, 2025 which is in 72 days.
How were Castle Biosciences’s earnings last quarter?
Castle Biosciences released its earnings results on Nov 04, 2024. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of -$0.004 by $0.084.
Is Castle Biosciences overvalued?
According to Wall Street analysts Castle Biosciences’s price is currently Undervalued.
Does Castle Biosciences pay dividends?
Castle Biosciences does not currently pay dividends.
What is Castle Biosciences’s EPS estimate?
Castle Biosciences’s EPS estimate is <$0.01.
How many shares outstanding does Castle Biosciences have?
Castle Biosciences has 28,007,301 shares outstanding.
What happened to Castle Biosciences’s price movement after its last earnings report?
Castle Biosciences reported an EPS of $0.08 in its last earnings report, beating expectations of -$0.004. Following the earnings report the stock price went down -7.402%.
Which hedge fund is a major shareholder of Castle Biosciences?
Among the largest hedge funds holding Castle Biosciences’s share is Deerfield Management Company, LP. It holds Castle Biosciences’s shares valued at 483K.
---
Castle Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.29 (56.11% Upside)
$42.29 (56.11% Upside)
Blogger Sentiment
Bullish
CSTL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 853.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.87%
12-Months-Change
Fundamentals
Return on Equity
1.47%
Trailing 12-Months
Asset Growth
18.01%
Trailing 12-Months
Company Description
Castle Biosciences
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
---
CSTL Company Deck
---
CSTL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Castle Biosciences reported strong financial performance with significant revenue and test volume growth across its portfolio. The company achieved positive cash flow and raised its revenue guidance for 2024. However, challenges regarding reimbursement, potential impact from recent hurricanes, and ongoing efforts to secure coverage for certain tests were noted.Read More>---
CSTL Stock 12 Month Forecast
Average Price Target
$42.29
▲(56.11% Upside)
Technical Analysis
Best Analysts Covering CSTL
1 Year
1 Year Success Rate
10/19 ratings generated profit
1 Year Average Return
+17.52%
reiterated a buy rating 2 months ago
Copying Mark Massaro's trades and holding each position for 1 Year would result in 52.63% of your transactions generating a profit, with an average return of +17.52% per trade.
---